| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 3rd December 2020 | Franklin M Berger | 6,534 | Exercise of derivative | $4.00 | $26,136.00 |
| 3rd December 2020 | Franklin M Berger | 2,184 | Exercise of derivative | $3.81 | $8,321.04 |
| 3rd December 2020 | Franklin M Berger | 6,773 | Exercise of derivative | $4.67 | $31,629.91 |
| 3rd December 2020 | Franklin M Berger | 25,000 | Exercise of derivative | $3.23 | $80,750.00 |
| 3rd December 2020 | Franklin M Berger | 1,716 | Exercise of derivative | $4.00 | $6,864.00 |
| 11th June 2020 | Franklin M Berger | 100,000 | Open or private purchase | $5.50 | $550,000.00 |
| 11th June 2020 | Talent Investments Ltd Equal | 1,454,545 | Open or private purchase | $5.50 | $7,999,997.50 |
| 4th February 2020 | Christopher J. Kirk | 38,461 | Open or private purchase | $2.60 | $99,998.60 |
| 4th February 2020 | Venture Investments Ltd Morningside | 3,800,000 | Open or private purchase | $2.60 | $9,880,000.00 |
| 4th February 2020 | Franklin M Berger | 120,846 | Open or private purchase | $2.60 | $314,199.60 |
Kezar Life Sciences
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company. The firm specializes in the areas of protein degradation and protein secretion. Its product include KZR-616, an immunoproteasome inhibitor.
Ticker: KZR
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1645666
Employees: 40
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $17 M (15%)
Marketable Securities, Current: $140 M (121%)
Other Assets, Current: $1 M (25%)
Assets, Current: $161 M (97%)
Property, Plant and Equipment, Net: $4 M (0%)
Other Assets, Noncurrent: $282 Th (0%)
Assets: $168 M (88%)
Accounts Payable, Current: $1 M (22%)
Accrued Liabilities, Current: $3 M (0%)
Liabilities, Current: $5 M (-15%)
Liabilities: $10 M (-12%)
Common Stock, Value, Issued: $46 Th (142%)
Common Stock, Shares, Issued: $46 M (138%)
Additional Paid in Capital, Common Stock: $262 M (61%)
Retained Earnings (Accumulated Deficit): $104 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $25 Th (-87%)
Stockholders' Equity (Parent): $158 M (0%)
Liabilities and Equity: $168 M (88%)
Research and Development: $7 M (-51%)
General and Administrative Expenses: $3 M (-52%)
Operating Income/Loss: $10 M (-51%)
News
Kezar Life Sciences: Keyed In On Autoimmune Therapies
6th November 2020
DXP Enterprises Reports Third Quarter 2020 Results
6th November 2020
17 Arrested For Running Fake Call Centre In Delhi: Police
6th November 2020
Ubiquiti Inc. Reports First Quarter Fiscal 2021 Financial Results
6th November 2020
